Advanced search×

Molecular genetic analysis of Down syndrome

Hum Genet 126(1):195-214 (2009) PMID 19526251

Down syndrome (DS) is caused by trisomy of all or part of human chromosome 21 (HSA21) and is the most common genetic cause of significant intellectual disability. In addition to intellectual disability, many other health problems, such as congenital heart disease, Alzheimer's disease, leukemia, hypotonia, motor disorders, and various physical anomalies occur at an elevated frequency in people with DS. On the other hand, people with DS seem to be at a decreased risk of certain cancers and perhaps of atherosclerosis. There is wide variability in the phenotypes associated with DS. Although ultimately the phenotypes of DS must be due to trisomy of HSA21, the genetic mechanisms by which the phenotypes arise are not understood. The recent recognition that there are many genetically active elements that do not encode proteins makes the situation more complex. Additional complexity may exist due to possible epigenetic changes that may act differently in DS. Numerous mouse models with features reminiscent of those seen in individuals with DS have been produced and studied in some depth, and these have added considerable insight into possible genetic mechanisms behind some of the phenotypes. These mouse models allow experimental approaches, including attempts at therapy, that are not possible in humans. Progress in understanding the genetic mechanisms by which trisomy of HSA21 leads to DS is the subject of this review.

DOI: 10.1007/s00439-009-0696-8
Version: za2963e q8za8 q8zb9 q8zce q8zd2 q8ze0 q8zfe q8zg7

Similar articles you may find interesting…

  1. The platelet proteome.

    Curr Opin Hematol 16(5):329-33 (2009) PMID 19550320

    Over 1100 platelet proteins have been identified using proteomic techniques. Various subproteomes have been characterized, including platelet releasates (the 'secretome'), alpha and dense granules, membrane and cytoskeletal proteins, platelet-derived microparticles, and the platelet 'phosphoproteome...
  2. Quantitative mass spectrometry-based techniques for clinical use: Biomarker identification and quantification☆

    BIOMED APPL 877(13):1240-1249 (2009) PMID 19058768

  3. Global and site-specific quantitative phosphoproteomics: principles and applications.

    Annu Rev Pharmacol Toxicol (2009) PMID 18834307

    We review enrichment strategies and methods for mass spectrometric fragmentation and analysis of phosphopeptides. We also describe different quantitative methods and their application to problems in cell signaling and drug target discovery. Emerging phosphoproteomics technologies are becoming more c...